Evidence map›Paper›PMID 38188949›Full record

ArticleRadiology case reports2024

Early-onset herpes simplex encephalitis type 1 triggered by COVID-19 disease: A case report.

Kai Inoue, Hanako Aoki, Shuta Toru, Yu Hatano, Reina Imase, Hiroshi Takasaki, Michiko Tanaka, Saori Adachi, Hiroaki Yokote, Hideki Akiyama and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kai InoueDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Hanako AokiDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Shuta ToruDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Yu HatanoDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Reina ImaseDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Hiroshi TakasakiDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Michiko TanakaDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Saori AdachiDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Hiroaki YokoteDepartment of Neurology, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Hideki AkiyamaDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Michio YamaneDepartment of Internal Medicine, Nitobe Memorial Nakano General Hospital, Nakano-ku, Tokyo, Japan.
Nitobe Memorial Nakano General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) causes a systemic inflammatory response and a temporary immunosuppression of hosts. Several reports have showed that reactivation of herpes simplex virus type 1 (HSV-1) is strongly associated with COVID-19. We present a case of a 66-year-old female, who developed HSV-1 encephalitis, showing impaired consciousness and typical MRI findings such as hyperintense lesions in the temporal lobe, insular cortices, bilateral medial frontal lobe on diffusion-weighted imaging, 7 days after the onset of COVID-19 symptoms. The number of cases of encephalitis in patients with COVID-19 is increasing. However, there has been limited reports of HSV-1 encephalitis following COVID-19, especially for cases with an interval of 7 days or less from the onset of COVID-19 symptoms to the onset of HSV-1 encephalitis. Our case highlights the importance of considering HSV-1 encephalitis in the differential when managing a patient with COVID-19-associated neurologic complications, even if it is in the early stages of COVID-19.

Indexed as

AcyclovirCOVID-19HSV-1 encephalitisReactivationVidarabine

Identifiers

PMID38188949
PMCPMC10770472
OpenAlexW4389775086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.